BSE filing, NSE: KUSUMGAR. Summary written from the filing by ALFA Finder's alert engine.
Kusumgar Ltd: key numbers
- Share price
- ₹554.50
- Market cap
- ₹5,822 Cr
- Revenue (annual)
- ₹692.0 Cr
- Net profit (annual)
- ₹98.20 Cr
- Promoter holding
- 75.01%
- FII holding
- 1.24%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kusumgar Ltd
All →Kusumgar Credit Rating
Kusumgar clarifies CRISIL has no rating mandate, attaching CARE's reaffirmed CARE A; Stable rating on its bank facilities. Company requests exchanges to note only CARE is engaged.
Kusumgar Annual General Meeting
Kusumgar Limited has announced the postal ballot voting results, confirming the ratification of the 'Kusumgar ESOP 2024' scheme and related stock option grants.
Kusumgar Annual General Meeting
Kusumgar Limited issued a Postal Ballot notice seeking shareholder approval to ratify the 'Kusumgar ESOP 2024' scheme and grant stock options to Group company employees.
Kusumgar Investor Presentation: Key Takeaways
Kusumgar reported stellar Q1 FY27 results with 102% YoY revenue growth, driven by specialized parachute contracts and scaling aerospace solutions. Management maintains a conservative outlook on guidance due to tender unpredictability.
Kusumgar Earnings Call Transcript: Key Takeaways
Kusumgar reported triple-digit YoY growth driven by a one-time parachute contract overflow and high-margin defense sales, but sequential revenue fell 21%, revealing inherent quarterly volatility.
Kusumgar Investor Presentation: Key Takeaways
Kusumgar Ltd reported strong Q1 FY27 results with 102% YoY revenue growth driven by parachute contract execution and significant EBITDA margin expansion to 31.1%.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.